Ming Yao
Overview
Explore the profile of Ming Yao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
686
Citations
12532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao Y, Li H, Yao M, Tao C, Wan Q, Tao Y, et al.
J Phys Chem Lett
. 2025 Mar;
:2942-2949.
PMID: 40082257
Atomically precise metal nanoclusters bridge the gap between metal atoms and metal nanoparticles, providing an ideal platform for correlating the macroscopic properties of metal nanoparticles to their microstructures. In comparison...
2.
Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T, et al.
Hepatology
. 2025 Mar;
PMID: 40067690
No abstract available.
3.
Li H, Chen D, Deng J, Sun L, Zhu J, Fan H, et al.
Am J Case Rep
. 2025 Feb;
26:e946352.
PMID: 40012186
BACKGROUND Stroke is a leading cause of mortality worldwide and often results in complex sequelae. Peripheral circulation disorders in paralyzed limbs are particularly challenging, presenting as persistent cold sensations and...
4.
Yao M, Wei W, Qiao W, Zhang Y, Zhou X, Li Z, et al.
Adv Mater
. 2025 Feb;
:e2414894.
PMID: 39972958
Organic room temperature phosphorescence (ORTP) polymer materials have sparked considerable research interests in recent years, but their optical function is still limited for multi-mode optical imaging. Herein, a feasible and...
5.
Xue Z, Yao M, Chen K, Huang T, Li J, Chen J, et al.
Sci Rep
. 2025 Feb;
15(1):4188.
PMID: 39905151
Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular...
6.
Zhao C, Lu Z, Hua B, Yue J, Yang Q, Ni H, et al.
J Pain Res
. 2025 Feb;
18:525-526.
PMID: 39901969
No abstract available.
7.
Yao M, Wang Y, Cornwell L, Sims C, Allbritton N
Anal Chem
. 2025 Jan;
97(5):2981-2990.
PMID: 39874434
Cell-to-cell heterogeneity in lipid signaling underlies variations in response and recurrence for many cancers, including leukemias. A highly parallel, miniaturized thin-layer chromatographic platform capable of assaying single cells was developed....
8.
Lee W, Lin C, Cheng-Hong Tsai X, Tien F, Lo M, Kuo Y, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Jan;
PMID: 39863463
Background: Myelodysplastic syndromes/neoplasms (MDS) are a diverse group of clonal myeloid disorders. Advances in molecular technology lead to the development of new classification systems. However, large-scale epidemiological studies on MDS...
9.
Chang Y, Wang Y, Wei C, Chen Y, Lin H, Lin C, et al.
Hematol Oncol
. 2025 Jan;
43(1):e70040.
PMID: 39853812
Various prognostic scoring systems in myelofibrosis (MF) have been developed to guide clinical decision-making in MF. However, discrepancies between different scoring systems for individual patients remain poorly understood, which can...
10.
Liu M, Ren H, Yao D, Yao M, Jiang N, Fan S, et al.
J Neurol
. 2025 Jan;
272(2):127.
PMID: 39812691
No abstract available.